These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 10991851)

  • 21. Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.
    Ling JM; Chan EW; Lam AW; Cheng AF
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3567-73. PubMed ID: 14576119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype.
    Muñoz R; De La Campa AG
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2252-7. PubMed ID: 8891124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
    Heaton VJ; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.
    Pan XS; Yague G; Fisher LM
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3140-7. PubMed ID: 11600369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of fluoroquinolone resistance mechanism in Mycoplasma hominis isolated from urogenital samples in a Chinese hospital.
    Zhang H; Zheng L; Zhao J; Ding S; Xia Y
    J Med Microbiol; 2019 Feb; 68(2):206-210. PubMed ID: 30632961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
    Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.
    Pan XS; Ambler J; Mehtar S; Fisher LM
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2321-6. PubMed ID: 8891138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained In vitro.
    Dessus-Babus S; Bébéar CM; Charron A; Bébéar C; de Barbeyrac B
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2474-81. PubMed ID: 9756744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
    Nagai K; Davies TA; Dewasse BE; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2001 Sep; 48(3):365-74. PubMed ID: 11533001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
    Varon E; Janoir C; Kitzis MD; Gutmann L
    Antimicrob Agents Chemother; 1999 Feb; 43(2):302-6. PubMed ID: 9925523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR; Tapsall JW; White PA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.
    Weigel LM; Anderson GJ; Facklam RR; Tenover FC
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3517-23. PubMed ID: 11709333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
    Rafii F; Park M; Novak JS
    Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.
    Dubin DT; Fitzgibbon JE; Nahvi MD; John JF
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1631-7. PubMed ID: 10390214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Formation of M. hominis and A. laidlawii resistance to fluoroquinolones].
    Govorun VM; Gushchin AE; Ladygina VG; Abramycheva NIu; Topol' IuIu
    Mol Gen Mikrobiol Virusol; 1998; (3):16-9. PubMed ID: 9819821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.
    Kumagai Y; Kato JI; Hoshino K; Akasaka T; Sato K; Ikeda H
    Antimicrob Agents Chemother; 1996 Mar; 40(3):710-14. PubMed ID: 8851598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanism of fluoroquinolones resistance in Mycoplasma hominis clinical isolates.
    Meng DY; Sun CJ; Yu JB; Ma J; Xue WC
    Braz J Microbiol; 2014; 45(1):239-42. PubMed ID: 24948939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.